#None #Senaparib #IMPACT Therapeutics #Pharmanovia

IMPACT Therapeutics Partners with Pharmanovia

In a strategic move aimed at expanding the global reach of their cancer treatment, IMPACT Therapeutics has officially partnered with Pharmanovia. This exclusive agreement grants Pharmanovia rights to develop, manufacture, and market Senaparib across various regions including Europe, the Middle East, North Africa, Australia, and New Zealand. These regions represent significant areas of opportunity for advancing the treatment of advanced high-grade epithelial ovarian, fallopian tube, and primary peritoneal cancers.

Major Highlights of the Agreement

The partnership is not just a simple agreement; it paves the way for substantial financial benefits to IMPACT Therapeutics. The company stands to receive an initial payment as well as regulatory milestone payments that could add up to a staggering €423.5 million. This could include tiered royalty payments based on a proportion of net sales.

Furthermore, the agreement expands the availability of Senaparib to 66 countries, aligning with a broader strategy to provide advanced cancer therapies to more patients worldwide. The drug's marketing authorization application (MAA) from the European Medicines Agency (EMA) has already been accepted, and the approval is anticipated by the latter half of 2026. This approval will mark an important milestone for both companies, as it signifies the acknowledgment of Senaparib as a viable treatment option in the oncology landscape of Europe.

Making Waves in Oncology

For IMPACT Therapeutics, this exclusive partnership is a pivotal first step in making its validated treatment options accessible to patients beyond China's borders. The collaboration with Pharmanovia is expected to accelerate the launch of Senaparib within the respective regions. By leveraging Pharmanovia's expertise and established infrastructure, it aims to ensure that Senaparib reaches its target patient population promptly. This cooperation is anticipated to significantly enhance the visibility not only of Senaparib but also of IMPACT Therapeutics on a global scale.

As the need for effective cancer treatments grows, the commitment to delivering high-quality options is crucial. The partnership with Pharmanovia reflects a concerted effort by IMPACT Therapeutics to address unmet medical needs in oncology.

About Senaparib

Senaparib (IMP4297) is a novel and potent PARP1/2 inhibitor developed independently by IMPACT. Known for its excellent target selectivity and broad safety margin, Senaparib was granted approval by the Chinese drug authority in January 2025 for use as a first-line maintenance therapy for adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have shown a complete or partial response to platinum-based chemotherapy. After successfully entering the National Reimbursement Drug List (NRDL) in December 2025, Senaparib continues to gain momentum in the market.

The license agreement with Pharmanovia is a testament to IMPACT's goal of advancing the clinical and regulatory development of Senaparib on a global scale. As the company continues to delve into lifecycle management and explore combination therapies for Senaparib, they are steadily expanding its indications alongside this partnership.

Company Overview

Founded in 2009, IMPACT Therapeutics is a commercially-focused biotechnology company that specializes in the development of precision cancer therapies based on synthetic lethality (SL). The company has developed one of the most comprehensive SL portfolios globally, along with being one of only three firms to possess both commercial-grade PARP1/2 inhibitors and next-generation PARP1-selective inhibitors in clinical phases.

With the core product Senaparib already on the market and undergoing constant development, IMPACT Therapeutics is well-positioned to address the pressing needs of cancer patients. Their strategic partnerships and commitment to innovation signify a forward-looking approach in the fight against cancer.